GlassScriptPhysician profile
Robert Lund Daniels
NPI 1386635969
$3,293.95
in general payments reported to CMS, 2019-2025
14 companies · $177 in 2025
The $177 reported for 2025 was less than what a typical Otology & Neurotology provider received nationally (typical 2025 total: $411).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,388 · 2020: $372 · 2021: $667 · 2022: $186 · 2023: $241 · 2024: $264 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $682.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $681.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cochlear Americas | $1,558.17 | 2019-2025 | Osia Osi300 Implant, Baha, Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode |
| Advanced Bionics, LLC | $1,010.92 | 2019-2025 | Hires Ultra Ci Hifocus Ms Electrode |
| Med-El Corporation | $245.78 | 2019-2024 | Bci 602 Kit, Mi1250 Synchrony 2 Flexsoft |
| Regeneron Healthcare Solutions, INC. | $147.03 | 2021-2024 | Dupixent |
| Acclarent, INC | $103.41 | 2019-2022 | |
| Stryker Corporation | $64.30 | 2021 | |
| Xoran Technologies LLC | $36.25 | 2021 | |
| Nevro Corp. | $33.28 | 2024 | Senza |
| Teva Pharmaceuticals USA, INC. | $24.21 | 2021 | |
| Alk-Abello, INC | $16.10 | 2021 | |
| Optinose US, INC. | $15.06 | 2022 | |
| Lilly USA, LLC | $14.85 | 2021 | |
| Fortovia Therapeutics, INC. | $12.89 | 2020 | |
| Medtronic, INC. | $11.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Daniels listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.